Qiagen, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.1M
Doctors Paid
1,662
Transactions
3,282
2024 Total
$1.0M
Payment Breakdown by Category
Consulting$1.8M (34.7%)
Research$1.6M (30.5%)
Food & Beverage$65,813 (1.3%)
Royalty/License$62,938 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.8M | 511 | 34.7% |
| Unspecified | $1.6M | 60 | 30.5% |
| Space rental or facility fees (teaching hospital only) | $725,311 | 38 | 14.2% |
| Debt forgiveness | $514,597 | 536 | 10.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $349,868 | 19 | 6.8% |
| Food and Beverage | $65,813 | 2,054 | 1.3% |
| Royalty or License | $62,938 | 31 | 1.2% |
| Education | $26,834 | 16 | 0.5% |
| Honoraria | $22,732 | 13 | 0.4% |
| Gift | $7,573 | 2 | 0.1% |
| Long term medical supply or device loan | $1,747 | 1 | 0.0% |
| Grant | $650.00 | 1 | 0.0% |
Payments by Type
General
$3.6M
3,222 transactions
Research
$1.6M
60 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| NEUMODX 4PLEX V2 | $223,074 | 0 | 6 |
| Evaluation of 4th Generation QuantiFERON TB Test | $135,752 | 0 | 1 |
| Correlation between resistance gene signatures detected by the novel QIAstat-Dx BCID GN Plus AMR panel and phenotypic susceptibility against beta-lactam and non-beta-lactam antimicrobials | $100,000 | 0 | 1 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX SARS-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $90,183 | 0 | 2 |
| MULTI CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLU A B RSV SARS COV 2 VANTAGE ASSAY ONTHE NEUMODX MOLECULAR SYSTEMS | $88,381 | 0 | 4 |
| EVALUATION OF QIAGEN BKV ASRS ON THE NEUMODX MOLECULAR SYSTEM | $85,105 | 0 | 4 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX SARS-COV-2 ASSAY ON THE NEUMODX | $68,845 | 0 | 2 |
| Multi-Center Clinical Performance Evaluation of the NeuMoDx Flu-FluB-RSV-SARS CoV-2 Assay on the NeuMoDx Molecular Systems | $58,956 | 0 | 1 |
| EVALUATE NEUMODX EBV QUANT ASSAY | $56,956 | 0 | 1 |
| MULTICENTER STUDY, USING PROSPECTIVELY COLLECTED AND RESIDUAL NASOPHARYNGEAL SWAB SPECIMENS COLLECTED FROM SYMPTOMATIC INDIVIDUALS TO EVALUATE THE CLINICAL PERFORMANCE OF THE NEUMODX FLU A-B/RSV/SARS-COV-2 VANTAGE ASSAY ON THE NEUMODX SYSTEMS | $56,451 | 0 | 1 |
| COMPARISON OF QIASTAT-DX RESPIRATORY PANEL ASSAY WITH OTHER MULTIPLEX ASSAYS FOR DETECTION OF VIRAL PATHOGENS | $46,718 | 0 | 2 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLUA/FLUB/RSV/SARS-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $43,949 | 0 | 1 |
| AN OBSERVATIONAL, MULTI-CENTER, PROSPECTIVE AND RETROSPECTIVE CLINICAL STUDY TO EVALUATE THE PERFORMANCE OF THE NEUMODX EBV QUANT ASSAY V2.0 ON THE NEUMODX MOLECULAR SYSTEMS IN IMMUNOCOMPROMISED TRANSPLANT PATIENTS | $26,660 | 0 | 1 |
| QIASTAT-DX CUTI PLUS AMR PANEL CLINICAL PERFORMANCE | $26,009 | 0 | 1 |
| A CLINICAL STUDY TO EVALUATE NEUMODX EBV QUANT ASSAY | $22,165 | 0 | 2 |
| MULTI-CENTER CLINICAL PERFORMANCE EVALUATION OF THE NEUMODX FLUA-FLUB-RSV-SEVERE ACUTE RESPIRATORY SYNDROME-COV-2 ASSAY ON THE NEUMODX MOLECULAR SYSTEMS | $15,200 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Ross Levine, Md, MD | Internal Medicine | New York, NY | $630,430 | $0 |
| Dr. Richard White, Md, MD | Internal Medicine | New York, NY | $185,500 | $0 |
| Mikael Rinne, M.d., Ph.d, M.D., PH.D | Neurology | Boston, MA | $146,400 | $0 |
| Loyce Masae Kawamura, Md, MD | Internal Medicine | San Francisco, CA | $145,294 | $0 |
| Dr. David Barbie, Md, MD | Hematology & Oncology | Boston, MA | $114,000 | $0 |
| Dr. Robert Lindsley, Md, Phd, MD, PHD | Medical Oncology | Boston, MA | $96,674 | $0 |
| Dr. Andrew Lane, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Boston, MA | $91,950 | $0 |
| Dr. Thanh Barbie, Md, MD | Surgery | Boston, MA | $90,000 | $0 |
| Ryan Corcoran, Md, Phd, MD, PHD | Internal Medicine | Boston, MA | $88,500 | $0 |
| Dr. Cesar Castro, M.d., M.sc, M.D., M.SC | Medical Oncology | Boston, MA | $85,500 | $0 |
| Sarojini Qasba, Md, Mph, MD, MPH | Hospitalist | Bethesda, MD | $47,186 | $0 |
| Dr. Camille Kotton, Md, MD | Internal Medicine | Boston, MA | $13,400 | $0 |
| Dr. Lindsay Cameron, Md, Mph, MD, MPH | Pediatrics | Houston, TX | $9,500 | $0 |
| Dr. Craig Platt, M.d./Ph.d, M.D./PH.D | Pediatric Allergy/Immunology | Boston, MA | $6,000 | $0 |
| Dr. Kalpana Gupta, Md, MD | Infectious Disease | West Haven, CT | $5,047 | $0 |
| Dr. Payal Patel, M.d, M.D | Infectious Disease | Ann Arbor, MI | $4,865 | $0 |
| Mr. Alawode Oladele, Md, MD | Public Health & General Preventive Medicine | Decatur, GA | $4,726 | $0 |
| Anjen Chenn, Md, MD | Clinical Pathology/Laboratory Medicine | Chicago, IL | $4,000 | $0 |
| Dr. Albert Riddle, Md, MD | Geriatric Medicine | Haworth, NJ | $3,907 | $0 |
| Dr. Corrado Altomare, Md, MD | Research Study | Flemington, NJ | $3,330 | $0 |
| Dr. Peter Nigrovic, Md, MD | Rheumatology | Boston, MA | $3,199 | $0 |
| Richard Press, Md, MD | Molecular Genetic Pathology | Portland, OR | $3,179 | $0 |
| Gregory Moran, Md, MD | Emergency Medicine | Northridge, CA | $3,152 | $0 |
| Amy Fox, Md, MD | Pediatric Nephrology | Bronx, NY | $3,035 | $0 |
| Benjamin Bradley, M.d., Ph.d, M.D., PH.D | Anatomic Pathology & Clinical Pathology | Salt Lake City, UT | $3,000 | $0 |
Ad
Top Products
- MDx Quantiferon $135,752
- QUANTIFERON $50,406
Associated Products (8)
- QUANTIFERON $50,406
- QUNATIFERON-SARS-COV-2 $33,750
- QIAREACH SARS-COV-2 ANTIGEN TEST $24,769
- NEUMODX EBV QUANT ASSAY $19,760
- MDX QUANTIFERON $19,383
- QIAstat-Dx Respiratory Panel $16,667
- QIAREACH ANTI-SARS-COV-2 TOTAL TEST $15,660
- QUANTIFERON-TB GOLD PLUS $12,427
Payment Categories
- Food & Beverage $65,813
- Consulting $1.8M
- Research $1.6M
- Royalties $62,938
About Qiagen, LLC
Qiagen, LLC has made $5.1M in payments to 1,662 healthcare providers, recorded across 3,282 transactions in the CMS Open Payments database. In 2024, the company paid $1.0M. The top product by payment volume is MDx Quantiferon ($135,752).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 254 doctors).
Payment categories include: Food & Beverage ($65,813), Consulting ($1.8M), Research ($1.6M), Royalties ($62,938).
Qiagen, LLC is associated with 8 products in the CMS Open Payments database, including QUANTIFERON, QUNATIFERON-SARS-COV-2, and QIAREACH SARS-COV-2 ANTIGEN TEST.